July 01, 2015
Xellia Pharmaceuticals ApS' generic version of the anti-fungal medication Cancidas infringes on one of the patents held by Merck Sharp & Dohme Corp., a Delaware federal judge ruled on Tuesday.
February 18, 2014
Merck Sharp & Dohme Corp. targeted drug manufacturer Xellia Pharmaceuticals ApS with a lawsuit in Delaware federal court on Friday, alleging that the generics company's proposed version of the anti-fungal medication Cancidas will infringe on one of Merck's patents.